Lorundrostat
-
Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive late-stage clinical trial showed promise for its new…
-
Mineralys in Radnor Raises $192M for Blood Pressure Drug
A public stock offering from Mineralys Therapeutics of Radnor netted $192 million for the company’s development of a new blood pressure drug candidate, lorundrostat, writes…
-
Mineralys in Radnor Raises Funds for new Blood Pressure Treatment
Mineralys Therapeutics, a Radnor biopharmaceutical company is hoping to raise $100 million to develop a new high blood pressure treatment, writes John George for Philadelphia…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
